Mapping Driver Mutations to Histopathological Subtypes in Papillary Thyroid Carcinoma: Applying a Deep Convolutional Neural Network

Mapping Driver Mutations to Histopathological Subtypes in Papillary Thyroid Carcinoma: Applying a Deep Convolutional Neural Network

Papillary thyroid carcinoma (PTC) is the most common subtype of thyroid cancers and informative biomarkers are critical for risk stratification and treatment guidance. About half of PTCs harbor <i>BRAF<sup>V600E</sup></i> and 10%−15% have <i>RAS</i> muta...

Full description

Bibliographic Details
Main Authors:	Peiling Tsou, Chang-Jiun Wu
Format:	Article
Language:	English
Published:	MDPI AG 2019-10-01
Series:	Journal of Clinical Medicine
Subjects:	papillary thyroid carcinoma histopathology <i>braf<sup>v600e</sup></i> <i>ras</i> deep learning convolutional neural network
Online Access:	https://www.mdpi.com/2077-0383/8/10/1675

Similar Items

Correlations between Molecular Landscape and Sonographic Image of Different Variants of Papillary Thyroid Carcinoma
by: Andrzej Lewiński, et al.
Published: (2019-11-01)

BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells
by: Elisa Bonaldi, et al.
Published: (2021-05-01)

Prospective Analysis of <i>TERT</i> Promoter Mutations in Papillary Thyroid Carcinoma at a Single Institution
by: Yun-Suk Choi, et al.
Published: (2021-05-01)

Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1,587 patients
by: Xiangqian Zheng, et al.
Published: (2019-03-01)

Genetic Landscape of Papillary Thyroid Carcinoma and Nuclear Architecture: An Overview Comparing Pediatric and Adult Populations
by: Aline Rangel-Pozzo, et al.
Published: (2020-10-01)

<i>BRAF</i><sup>V600E</sup> <i>vs</i>. TIRADS in predicting papillary thyroid cancers in Bethesda system I, III, and V nodules
by: Ya Wu, et al.
Published: (2019-03-01)

BRAF<sup>V600E</sup> status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China
by: Zheng Xiangqian, et al.
Published: (2012-06-01)

Characterization and Clinical Utility of <i>BRAF</i><sup>V600</sup> Mutation Detection Using Cell-Free DNA in Patients with Advanced Melanoma
by: Piotr Rutkowski, et al.
Published: (2021-07-01)

Analysis of the Role of FRMD5 in the Biology of Papillary Thyroid Carcinoma
by: Agata M. Gaweł, et al.
Published: (2021-06-01)

TNF-α May Exert Different Antitumor Effects in Response to Radioactive Iodine Therapy in Papillary Thyroid Cancer with/without Autoimmune Thyroiditis
by: Dan Cristian Gheorghe, et al.
Published: (2021-07-01)

<i>Snail-1</i> Overexpression Correlates with Metastatic Phenotype in BRAF<sup>V600E</sup> Positive Papillary Thyroid Carcinoma
by: Katarzyna Wieczorek-Szukala, et al.
Published: (2020-08-01)

Association of MicroRNA Expression and BRAF<sup>V600E</sup> Mutation with Recurrence of Thyroid Cancer
by: Daina Pamedytyte, et al.
Published: (2020-04-01)

<i>TERT</i> Promoter Mutation and Extent of Thyroidectomy in Patients with 1–4 cm Intrathyroidal Papillary Carcinoma
by: Aya Ebina, et al.
Published: (2020-07-01)

<i>TERT</i> Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma
by: Pauline Blateau, et al.
Published: (2020-08-01)

Prognostic Significance of COX-2 Overexpression in <i>BRAF</i>-Mutated Middle Eastern Papillary Thyroid Carcinoma
by: Sandeep Kumar Parvathareddy, et al.
Published: (2020-12-01)

Genetic Determinants for Prediction of Outcome of Patients with Papillary Thyroid Carcinoma
by: Antónia Afonso Póvoa, et al.
Published: (2021-04-01)

Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients
by: Dagmara Rusinek, et al.
Published: (2018-09-01)

BRAF V600E expression found in aggressive papillary thyroid carcinoma (PTC), lymph node metastasis, and extra-thyroid extension
by: Made Priska Rusmana, et al.
Published: (2018-10-01)

Extended Antitumor Responseof a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
by: Siraj M. Ali, et al.
Published: (2014-05-01)

Coexisting Germline <i>CHEK2</i> and Somatic <i>BRAF</i><sup>V600E</sup> Mutations in Papillary Thyroid Cancer and Their Association with Clinicopathological Features and Disease Course
by: Danuta Gąsior-Perczak, et al.
Published: (2019-11-01)

Rethinking the role of oncogenes in papillary thyroid cancer initiation
by: Mario eVitale
Published: (2012-06-01)

The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer
by: Maryam Zarkesh, et al.
Published: (2018-12-01)

Prevalence of BRAF Mutation in Papillary Thyroid Cancer
by: Shatha Dmour, et al.
Published: (2016-12-01)

Long-Term Prognostic Value of the Response to Therapy Assessed by Laboratory and Imaging Findings in Patients with Differentiated Thyroid Cancer
by: Michele Klain, et al.
Published: (2021-08-01)

<i>BRAF</i> Exon 15 Mutations in Papillary Carcinoma and Adjacent Thyroid Parenchyma: A Search for the Early Molecular Events Associated with Tumor Development
by: Giorgia Acquaviva, et al.
Published: (2020-02-01)

The Diagnostic Usefulness of <sup>131</sup>I-SPECT/CT at Both Radioiodine Ablation and during Long-Term Follow-Up in Patients Thyroidectomized for Differentiated Thyroid Carcinoma: Analysis of Tissue Risk Factors Ascertained at Surgery and Correlated with Metastasis Appearance
by: Angela Spanu, et al.
Published: (2021-08-01)

Genomic characterization of high-recurrence risk papillary thyroid carcinoma in a southern Chinese population
by: Min Li, et al.
Published: (2020-05-01)

Short-Term Probiotic Administration Increases Fecal-Anti <i>Candida</i> Activity in Healthy Subjects
by: Massimiliano De Angelis, et al.
Published: (2019-06-01)

Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma
by: Changjiao Yan, et al.
Published: (2019-07-01)

Concomitant BRAF Mutation in Hairy Cell Leukemia and Papillary Thyroid Cancer: Case Report
by: Shehab F. Mohamed, et al.
Published: (2019-12-01)

Analysis of Recurrence Factor of Postoperative Papillary Thyroid Cancer
by: XING Lan-lan;CHEN Song;LI Ya-ming
Published: (2014-02-01)

Correlation between F18-FDG PET/CT Imaging and BRAF V600E Genetic Mutation for the Early Assessment of Treatment Response in Papillary Thyroid Cancers
by: Andra Piciu, et al.
Published: (2020-06-01)

Correlation of the BRAFV600E and RAS mutations with clinicopathological characteristics of papillary thyroid cancer using TCGA database analysis
by: Yue Zhao, et al.
Published: (2019-01-01)

<i>TERT</i> Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma
by: Dagmara Rusinek, et al.
Published: (2020-06-01)

Evaluation of Radioiodinated Fluoronicotinamide/Fluoropicolinamide-Benzamide Derivatives as Theranostic Agents for Melanoma
by: Chao-Cheng Chen, et al.
Published: (2020-09-01)

Characterization of Bottled Waters by Multielemental Analysis, Stable and Radiogenic Isotopes
by: Tea Zuliani, et al.
Published: (2020-08-01)

Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
by: Woon Won Kim, et al.
Published: (2018-01-01)

Predictive Factors of Recurrence for Multifocal Papillary Thyroid Microcarcinoma With Brafv600e Mutation: A Single Center Study of 1,207 Chinese Patients
by: Shuai Xue, et al.
Published: (2019-06-01)

Influence of <i>Clear<sup>T</sup></i> and<i> Clear<sup>T2</sup></i> Agitation Conditions in the Fluorescence Imaging of 3D Spheroids
by: Daniel N. Silva, et al.
Published: (2021-12-01)

Studies of Conorfamide-Sr3 on Human Voltage-Gated Kv1 Potassium Channel Subtypes
by: Estuardo López-Vera, et al.
Published: (2020-08-01)